| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| 500g |
|
||
| Other Sizes |
| Targets |
4,4'-Oxydiphenol has no defined biological target as a drug. It is an organic building block and a pharmaceutical intermediate. The phenolic hydroxyl groups can act as antioxidants by scavenging free radicals. As a diphenyl ether derivative, it may have weak estrogenic activity by binding to estrogen receptors, but this is not its primary use. It is not a drug; its primary applications are in materials science and organic synthesis. It is used as an intermediate in the production of pharmaceuticals, agrochemicals, and specialty chemicals.
|
|---|---|
| ln Vitro |
4,4'-Oxydiphenol is not a drug and does not exhibit direct in vitro biological activity as a therapeutic agent. It is a chemical intermediate used in the synthesis of other bioactive compounds. In cell-free systems, it may be used as a substrate for laccase or peroxidase enzymes in polymerization reactions. No enzyme inhibition or cell-based activity is reported. Specific IC₅0 values are not available. It can be used as a monomer in the synthesis of polymers.
|
| ln Vivo |
4,4'-Oxydiphenol is not used in vivo as a drug. It is a chemical intermediate used in the production of pharmaceuticals, including anti-inflammatory drugs. No therapeutic in vivo activity is reported. For environmental toxicity studies, it may be used as a reference standard for the analysis of diphenyl ethers in environmental samples. The compound is not intended for systemic administration as a drug.
|
| Enzyme Assay |
Not applicable. 4,4'-Oxydiphenol is a chemical intermediate and is not evaluated in standard biological enzyme or receptor binding assays. Its purity (>98% by GC) is assessed by GC or HPLC. ¹H NMR and ¹3C NMR (in DMSO-d₆) confirm the structure, with characteristic signals for the aromatic protons (delta 6.8-7.3 ppm) and the phenolic OH protons (delta 9.5 ppm). Physicochemical properties: MW 202.21, LogP ~3-4, melting point 163-170degC, boiling point 379.2degC, soluble in organic solvents (methanol, DMSO), slightly soluble in water. No biological assays are applicable.
|
| Cell Assay |
Not applicable. 4,4'-Oxydiphenol is not used in standard cell-based assays for drug discovery. For toxicity screening, HepG2 or HEK293 cells are seeded in 96-well plates (1×10⁴ cells/well) and treated with 4,4'-Oxydiphenol (1-1000 uM) for 24-72 h. Cell viability is measured by MTT assay. The CC₅0 is expected to be >200 uM, indicating low to moderate cytotoxicity. This testing is for safety assessment only. For polymerization studies, it is used as a monomer.
|
| Animal Protocol |
No in vivo animal protocol for 4,4'-Oxydiphenol exists, as it is not a drug candidate. For acute toxicity testing (if required for safety classification), female Sprague-Dawley rats (n=3-5 per dose) are administered a single oral dose of 4,4'-Oxydiphenol in corn oil at 500, 1000, 2000, 5000 mg/kg and observed for 14 days for mortality and clinical signs. The LD₅0 is expected to be >2000 mg/kg (low acute toxicity). Dermal and ocular irritation tests may also be conducted for industrial safety classification.
|
| ADME/Pharmacokinetics |
No specific PK data for 4,4'-Oxydiphenol is available. As a lipophilic molecule (LogP ~3-4), it would be absorbed if ingested. Metabolism would likely occur via Phase II conjugation (glucuronidation, sulfation) of the phenolic hydroxyl groups. The half-life is expected to be 2-6 hours. The compound is not intended for systemic administration. For research use, it is supplied as a solid (powder or crystalline).
|
| Toxicity/Toxicokinetics |
For 4,4'-Oxydiphenol, GHS pictogram: Warning. Hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation). Precautionary statements: P264 (Wash skin thoroughly after handling), P280 (Wear protective gloves/ eye protection/ face protection), P302 + P352 (IF ON SKIN: Wash with plenty of water), P305 + P351 + P338 (IF IN EYES: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; continue rinsing). Storage: at room temperature (recommended in a cool and dark place, <15degC) in a tightly sealed container.
|
| References | |
| Additional Infomation |
4,4'-Oxydiphenol (4,4'-Dihydroxydiphenyl ether; CAS# 1965-09-9) is a research-grade organic building block and pharmaceutical intermediate. It is not an FDA-approved drug. It is used as an intermediate in the synthesis of pharmaceuticals, liquid crystals, and epoxy resins. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C12H10O3
|
|---|---|
| Molecular Weight |
202.21
|
| Exact Mass |
202.063
|
| CAS # |
1965-09-9
|
| PubChem CID |
16069
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
159
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1O)OC2=CC=C(C=C2)O
|
| InChi Key |
NZGQHKSLKRFZFL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10O3/c13-9-1-5-11(6-2-9)15-12-7-3-10(14)4-8-12/h1-8,13-14H
|
| Chemical Name |
4-(4-hydroxyphenoxy)phenol
|
| Synonyms |
4,4'-Dihydroxydiphenyl ether
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9454 mL | 24.7268 mL | 49.4535 mL | |
| 5 mM | 0.9891 mL | 4.9454 mL | 9.8907 mL | |
| 10 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
